Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.
Nagy Á, Bátai B, Kiss L, Gróf S, Király PA, Jóna Á, Demeter J, Sánta H, Bátai Á, Pettendi P, Szendrei T, Plander M, Körösmezey G, Alizadeh H, Kajtár B, Méhes G, Krenács L, Timár B, Csomor J, Tóth E, Schneider T, Mikala G, Matolcsy A, Alpár D, Masszi A, Bödör C. Nagy Á, et al. Among authors: schneider t. J Intern Med. 2023 Sep;294(3):295-313. doi: 10.1111/joim.13674. Epub 2023 Jun 8. J Intern Med. 2023. PMID: 37259686
[Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
Schneider T, Tóth E, Lovey J, Molnár Z, Deák B, Várady E, Csomor J, Matolcsy A, Lengyel Z, Petri K, Gaudi I, Rosta A. Schneider T, et al. Orv Hetil. 2011 May 8;152(19):735-42. doi: 10.1556/OH.2011.29091. Orv Hetil. 2011. PMID: 21498163 Hungarian.
Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).
Schneider T, Rosta A, Losonczy H, Radványi G, Ujj G, Egyed M, Illés Á, Jakucs J, Szerafin L, Gasztonyi Z, Masszi T, Iványi J, Demeter J, Dombi P, Tóth A, Borbényi Z. Schneider T, et al. Pathol Oncol Res. 2018 Apr;24(2):199-205. doi: 10.1007/s12253-017-0234-2. Epub 2017 Apr 21. Pathol Oncol Res. 2018. PMID: 28432650 Free article. Clinical Trial.
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program.
Varga G, Nagy Z, Demeter J, Kosztolányi S, Szomor Á, Alizadeh H, Deák B, Schneider T, Plander M, Szendrei T, Váróczy L, Illés Á, Bátai Á, Pető M, Mikala G. Varga G, et al. Among authors: schneider t. Pathol Oncol Res. 2019 Oct;25(4):1615-1620. doi: 10.1007/s12253-019-00607-2. Epub 2019 Feb 2. Pathol Oncol Res. 2019. PMID: 30712192 Free PMC article.
Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients.
Lovas S, Varga G, Farkas P, Masszi T, Wohner N, Bereczki Á, Adamkovich N, Borbényi Z, Szomor Á, Alizadeh H, Szaleczky E, Wolf K, Schneider T, Plander M, Szendrei T, Csacsovszki O, Csukly Z, Rajnics P, Egyed M, Nagy Z, Rejtő L, Illés Á, Mikala G, Váróczy L. Lovas S, et al. Among authors: schneider t. Int J Hematol. 2019 Nov;110(5):559-565. doi: 10.1007/s12185-019-02715-w. Epub 2019 Aug 7. Int J Hematol. 2019. PMID: 31392600
Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.
Bödör C, Alpár D, Marosvári D, Galik B, Rajnai H, Bátai B, Nagy Á, Kajtár B, Burján A, Deák B, Schneider T, Alizadeh H, Matolcsy A, Brandner S, Storhoff J, Chen N, Liu M, Ghali N, Csala I, Bagó AG, Gyenesei A, Reiniger L. Bödör C, et al. Among authors: schneider t. J Neuropathol Exp Neurol. 2020 Feb 1;79(2):176-183. doi: 10.1093/jnen/nlz125. J Neuropathol Exp Neurol. 2020. PMID: 31886867
Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
Bödör C, Kotmayer L, László T, Takács F, Barna G, Kiss R, Sebestyén E, Nagy T, Hegyi LL, Mikala G, Fekete S, Farkas P, Balogh A, Masszi T, Demeter J, Weisinger J, Alizadeh H, Kajtár B, Kohl Z, Szász R, Gergely L, Gurbity Pálfi T, Sulák A, Kollár B, Egyed M, Plander M, Rejtő L, Szerafin L, Ilonczai P, Tamáska P, Pettendi P, Lévai D, Schneider T, Sebestyén A, Csermely P, Matolcsy A, Mátrai Z, Alpár D. Bödör C, et al. Among authors: schneider t. Br J Haematol. 2021 Jul;194(2):355-364. doi: 10.1111/bjh.17502. Epub 2021 May 21. Br J Haematol. 2021. PMID: 34019713
Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers.
Varga G, Dávid Tóth A, Réka Szita V, Csukly Z, Hardi A, Gaál-Weisinger J, Nagy Z, Altai E, Rencsik A, Plander M, Szendrei T, Kórád K, Radványi G, Rottek J, Deák B, Szaleczky E, Schneider T, Kohl Z, Kosztolányi S, Alizadeh H, Lengyel Z, Modok S, Borbényi Z, Lovas S, Váróczy L, Illés Á, Rajnics P, Masszi T, Mikala G. Varga G, et al. Among authors: schneider t. Pathol Oncol Res. 2021 Apr 22;27:613264. doi: 10.3389/pore.2021.613264. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34257583 Free PMC article.
2,136 results